Dr. Chan on ExteNET Trial for HER2+ Breast Cancer

Arlene Chan, MD
Published: Sunday, Sep 27, 2015



Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

The phase III ExteNET trial randomized patients to 1 year of extended adjuvant treatment with oral agent neratinib at 240 mg daily versus placebo. Patients enrolled in the study had previously received trastuzumab-based adjuvant therapy. Disease-free survival was the primary endpoint.

Despite significant survival gains with trastuzumab, Chan says, up to 25% of patients will experience disease recurrence, suggesting the HER2-positive setting requires further interventions, such as neratinib.

SELECTED
LANGUAGE


Arlene Chan, MD, director, Mount Hospital at Perth, discusses the ExteNET trial, which looked at neratinib as extended adjuvant therapy in patients with early-stage HER2-positive breast cancer.

The phase III ExteNET trial randomized patients to 1 year of extended adjuvant treatment with oral agent neratinib at 240 mg daily versus placebo. Patients enrolled in the study had previously received trastuzumab-based adjuvant therapy. Disease-free survival was the primary endpoint.

Despite significant survival gains with trastuzumab, Chan says, up to 25% of patients will experience disease recurrence, suggesting the HER2-positive setting requires further interventions, such as neratinib.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Rapid Reviews in Oncology®: Practice-Changing Data in Acute Myeloid Leukemia: A Rapid Update From Atlanta OnlineDec 21, 20182.0
Community Practice Connections™: 2nd Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesDec 30, 20182.0
Publication Bottom Border
Border Publication
x